Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

The US Food and Drug Administration (FDA) has approved Boston Scientific’s expanded instructions for use (IFU) labelling of ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

In its first year on the market, Farapulse brought in more than $1 billion in revenue. Now Boston Scientific aims to double its reach to the full afib population.

Boston Scientific receives US FDA approval for expanded labelling of Farapulse PFA System: Marlborough, Massachusetts Tuesday, July 8, 2025, 11:00 Hrs [IST] Boston Scientific Corp ...

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston ...

Adjusted operating margin is expected to expand 50-75 basis points, driven by strong product mix, notably FARAPULSE and WATCHMAN, and cost efficiencies.

Boston Scientific secured FDA approval to expand its FARAPULSE system, strengthening its grip in atrial fibrillation ...

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ — Boston Scientific ...